Similar articles for PMID: 23729697

Year	Number of Results
1990	1
1993	1
1996	2
1997	1
1999	2
2000	1
2001	2
2002	2
2004	2
2005	5
2006	5
2007	10
2008	4
2009	6
2010	15
2011	23
2012	34
2013	35
2014	31
2015	42
2016	48
2017	32
2018	35
2019	31
2020	31
2021	26
2022	16
2023	5
2024	0

1

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR. Fendler WP, et al. J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31. J Nucl Med. 2013. PMID: 23729697 Free article.

2

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M. Haug AR, et al. J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13. J Nucl Med. 2012. PMID: 22331219 Free article.

3

The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.

Soydal C, Kucuk ON, Gecim EI, Bilgic S, Elhan AH. Soydal C, et al. Nucl Med Commun. 2013 May;34(5):501-6. doi: 10.1097/MNM.0b013e32835f9427. Nucl Med Commun. 2013. PMID: 23478586

4

Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.

Piduru SM, Schuster DM, Barron BJ, Dhanasekaran R, Lawson DH, Kim HS. Piduru SM, et al. J Vasc Interv Radiol. 2012 Jul;23(7):943-8. doi: 10.1016/j.jvir.2012.04.010. Epub 2012 May 19. J Vasc Interv Radiol. 2012. PMID: 22609292 Clinical Trial.

5

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T. Zerizer I, et al. Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30. Eur J Nucl Med Mol Imaging. 2012. PMID: 22644713

6

Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.

Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT. Shady W, et al. Eur J Radiol. 2016 Jun;85(6):1224-31. doi: 10.1016/j.ejrad.2016.03.029. Epub 2016 Mar 31. Eur J Radiol. 2016. PMID: 27161074 Free PMC article.

7

Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver.

Edalat F, Camacho JC, Kokabi N, Kendi AT, Galt JR, Kim HS. Edalat F, et al. Clin Nucl Med. 2016 Feb;41(2):e76-81. doi: 10.1097/RLU.0000000000000991. Clin Nucl Med. 2016. PMID: 26447380

8

Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?

Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D. Cook GJ, et al. J Nucl Med. 2013 Jan;54(1):19-26. doi: 10.2967/jnumed.112.107375. Epub 2012 Nov 30. J Nucl Med. 2013. PMID: 23204495 Free article.

9

Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.

Sager S, Akgün E, Uslu-Beşli L, Asa S, Akovali B, Sahin O, Yeyin N, Demir M, Abuqbeitah M, Gülsen F, Sayman H, Sönmezoglu K. Sager S, et al. Nucl Med Commun. 2019 May;40(5):461-468. doi: 10.1097/MNM.0000000000001014. Nucl Med Commun. 2019. PMID: 30896544

10

Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.

Tochetto SM, Töre HG, Chalian H, Yaghmai V. Tochetto SM, et al. AJR Am J Roentgenol. 2012 May;198(5):1093-9. doi: 10.2214/AJR.11.6622. AJR Am J Roentgenol. 2012. PMID: 22528898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

381 results

Results by year